These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 4448555)

  • 1. Propranolol therapy in essential hypertension. Observations on predictability of therapeutic response.
    Hansson L; Zweifler AJ; Julius S; Ellis CN
    Int J Clin Pharmacol; 1974 Sep; 10(2):79-89. PubMed ID: 4448555
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of essential hypertension with a new vasodilator in combination with beta-adrenergic blockade.
    Gilmore E; Weil J; Chidsey C
    N Engl J Med; 1970 Mar; 282(10):521-7. PubMed ID: 4391708
    [No Abstract]   [Full Text] [Related]  

  • 3. Beta-adrenergic blockade in essential hypertension. Effects of propranolol on hemodynamic parameters and plasma renin activity.
    Hansson L
    Acta Med Scand Suppl; 1973; 550():1-40. PubMed ID: 4201751
    [No Abstract]   [Full Text] [Related]  

  • 4. [Mechanism of the antihypertensive action of propranolol].
    Magnani B; Ambrosioni E; Branzi A; Maresta A; Picchio F; Russo F; Sanguinetti M
    Minerva Cardioangiol; 1973 Apr; 21(4):284-97. PubMed ID: 4710125
    [No Abstract]   [Full Text] [Related]  

  • 5. Hemodynamic studies on hypertension. II. Effects of isoproterenol, propranolol, noradrenaline and phentolamine on the hemodynamics in essential hypertension.
    Tsuchiya M
    Jpn Circ J; 1972 Mar; 36(3):275-88. PubMed ID: 5068095
    [No Abstract]   [Full Text] [Related]  

  • 6. Hemodynamic effects of acute and prolonged beta-adrenergic blockade in essential hypertension.
    Hansson L; Zweifler AJ; Julius S; Hunyor SN
    Acta Med Scand; 1974; 196(1-2):27-34. PubMed ID: 4370849
    [No Abstract]   [Full Text] [Related]  

  • 7. [Changes induced by acute and prolonged administration of propranolol in systemic hemodynamics in hypertensive patients].
    Branzi A; Sanguinetti M; Ambrosioni E; Magnani B
    Boll Soc Ital Cardiol; 1970; 15(6):627-33. PubMed ID: 5517658
    [No Abstract]   [Full Text] [Related]  

  • 8. Cardiovascular response in hyperthyroidism. The influence of adrenergic-receptor blockade.
    Pietras RJ; Real MA; Poticha GS; Bronsky D; Waldstein SS
    Arch Intern Med; 1972 Mar; 129(3):426-9. PubMed ID: 4401571
    [No Abstract]   [Full Text] [Related]  

  • 9. Haemodynamic changes in patients with coronary heart disease after beta-adrenergic blockade with propranolol.
    Bürgin D
    Int Z Klin Pharmakol Ther Toxikol; 1970 Oct; 4(4):365-70. PubMed ID: 4395489
    [No Abstract]   [Full Text] [Related]  

  • 10. [Evaluation of the effect of obsidan in essential hypertension patients with different types of circulation].
    Goloshchapov OA; Pribylova NN; Kotova LN; Nozhnova LP
    Ter Arkh; 1986; 58(11):29-32. PubMed ID: 3824185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular effects of nisoldipine in essential hypertension.
    Blau A; Herzog D; Herz I; Battler A; Schechter P; Eliahou HE
    Isr J Med Sci; 1994 Feb; 30(2):139-45. PubMed ID: 8150600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Trial of L-dopa as hypotensive medication in arterial hypertension. Preliminary report].
    Torres Zamora M; García Monterd G; Chávez Domínguez R; Chávez Lara B; Serrano PA
    Arch Inst Cardiol Mex; 1974; 44(2):267-74. PubMed ID: 4599277
    [No Abstract]   [Full Text] [Related]  

  • 13. Review of studies on the clinical pharmacodynamics of cilazapril.
    Belz GG; Breithaupt K; Erb K
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S14-9. PubMed ID: 7898090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurogenic maintenance of peripheral resistance in borderline hypertension.
    Julius S; Esler M; Randall OS; Ellis C
    Acta Physiol Lat Am; 1974; 24(5):425-31. PubMed ID: 4467668
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute hypotensive effects of oral and intravenous propranolol: early alterations in peripheral resistance.
    Fagan TC; Gourley LA; Sawyer PR; Lee JT; Walle T; Gaffney TE
    J Clin Hypertens; 1986 Mar; 2(1):21-9. PubMed ID: 3723158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ambulatory antihypertensive therapy using the beta-receptor blockader obsidan].
    Dück KD; Knappe J; Strube G
    Z Gesamte Inn Med; 1973 Aug; 28(16):Suppl:248-51. PubMed ID: 4767603
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of propranolol on circulatory hemodynamics of patients with coronary heart failure in the light of polycardiographic examination.
    Mazurowa A; Tracz W
    Pol Med J; 1970; 9(4):827-34. PubMed ID: 5477489
    [No Abstract]   [Full Text] [Related]  

  • 18. Blood pressure and vascular design in renal hypertension in rats after prolonged propranolol treatment.
    Lundgren Y
    Acta Physiol Scand; 1974 Jul; 91(3):409-16. PubMed ID: 4846333
    [No Abstract]   [Full Text] [Related]  

  • 19. Antihypertensive effects of propranolol. Observations on predictability.
    Birkenhäger WH; Krauss XH; Schalekamp MA; Kolsters G; Kroon BJ
    Folia Med Neerl; 1971; 14(2):67-71. PubMed ID: 5559125
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hemodynamic changes following blockade of the beta-receptors in healthy persons and in patients with coronary heart disease. Comparison between Trasicor and Inderal].
    Bürgin D
    Schweiz Med Wochenschr; 1968 Jun; 98(25):940-5. PubMed ID: 5699197
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.